Copy

Welcome

Welcome to the third issue of the ROADMAP newsletter!

 
As we approach the halfway point of ROADMAP Phase 1 we are thrilled about the exciting progress the project has made to date, and we look forward to upcoming conferences where you can meet the ROADMAP team and hear them report on the work done over the past twelve months.
This third issue of the ROADMAP newsletter will give you a progress update as well as insights into ROADMAP’s stakeholder involvement from the perspectives of industry, academia and people living with dementia to promote a fuller picture on the scope of real-world evidence.

We hope you enjoy this issue of the ROADMAP newsletter!

 

John Gallacher

Project Coordinator, Director of the MRC Dementia Platform UK and professor of Cognitive Health at the University of Oxford


 

Pick of the season

ROADMAP Stakeholder Partnerships: The Importance of regulatory engagement


Robin Thompson

Director, EU+ Value and Market Access at Biogen International

Today’s post is by Michael Happich (Director HTA BioMeds, Canada & Europe) at Eli Lilly & Robin Thompson (Director, EU+ Value and Market Access) at Biogen International. They will introduce us to the need to consider differing perspectives and subsequently the need for broader engagement in the creation of conditions for an open collaboration among stakeholders that yields consensual and efficient uses of real-world evidence for the benefit of AD patients and their caregivers.
Read more

Scientific involvement

Communications team co-lead introduces the WP2 consultation with the EWGPWD


Jean Georges

Executive Director of Alzheimer Europe
AE set up the European Working Group of People with Dementia (EWGPWD) in 2012 to provide feedback and advice to Alzheimer Europe and to ensure the views of people with dementia are duly included in its own work and various EU projects. The group is currently comprised of 10 people with different kinds of dementia and each member is nominated by a national Alzheimer’s association.  

At the beginning of September, we organised a meeting of the EWGPWD and the ROADMAP Outcomes Definition team. The following article gives you an outline of the interesting discussions and great feedback provided during the two days.

 
Read more


Further, this part of the newsletter features two interviews on scientific involvement from both the perspective of a scientist and people living with dementia.

In the first interview we talk to Mia Nelson (UEDIN) who is trying to unpick which outcomes are most important and most helpful in understanding the progression of Alzheimer’s disease.
 

 
The second interview features the experts by experience, Chris Roberts (EWGPWD Vice Chair) and his wife Jayne. They will give you insights into their thoughts during and about the consultation as well as what they think about the project itself.
 

Latest News

Join the ROADMAP team - vacancy as research assistant

 
We're excited to announce that Edinburgh University’s Usher Institute is recruiting a Research Assistant for ROADMAP! You will join Professor Cathie Sudlow’s team, based at Edinburgh University’s Usher Institute in the Bioquarter, Little France, produce high quality evidence of stakeholder views on the outcomes of AD and its progression by conducting a systematic review and stakeholder engagement activities.  The closing date is 3 October 2017.
 
Read more

ROADMAP progress update
The ROADMAP team has been busy since the last newsletter, and here we give you a brief overview and update of what has been happening across the work packages.
 
Read more

ROADMAP releases leaflet for external communication
ROADMAP's communications team has created a project leaflet for partners to use at conferences. The leaflet includes high-level information on the challenge the scientists are aiming to tackle with their work and the leading objectives behind it. A digital version of the leaflet is also available on our website. The aim of the leaflet is to raise awareness about the project and to provide a basis of contact for additional database providers, interested universities, institutions as well as companies, to further expand our Europe-wide network towards a potential onboarding for a Phase 2 of ROADMAP.
 
Read more

Events

Meet the ROADMAP team update
This section is dedicated to provide you direct access to detailed updates on all upcoming external ROADMAP presentations.
For an overview of upcoming events visit the events section on our website: http://roadmap-alzheimer.org/events/
 
Read more
@IMI2_ROADMAP
http://roadmap-alzheimer.org/
info@roadmap-alzheimer.org

Copyright © 2017 ROADMAP, All rights reserved.

Our mailing address is:
info@roadmap-alzheimer.org
Sign up for our list!
Want to change how you receive these emails?
You can update your preferences or unsubscribe from this list

 
This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 116020 (“ROADMAP”). This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.






This email was sent to <<Email Address>>
why did I get this?    unsubscribe from this list    update subscription preferences
ROADMAP · Alzheimer Europe · 14 rue Dicks · Luxembourg L-1417 · Luxembourg

Email Marketing Powered by Mailchimp